Navigation Links
Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
Date:7/23/2009

Zdechlik was Founding member of the U.S. Clinical Molecular Diagnostic Group

NEW YORK, July 23 /PRNewswire-USNewswire/ -- Exosome Diagnostics, Inc., the developer of non-invasive molecular oncology diagnostics to aid in early cancer detection and therapeutic selection, announced today that Greg Zdechlik has been named Chief Operating Officer. As COO, Zdechlik will be responsible for driving diagnostic development, commercial relations, and product introduction including Exosome's new blood based EGFR, KRAS and BRAF assays.

"Greg brings considerable industry expertise to our operating team," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "His track record of developing and growing platform technologies, including Roche's highly successful PCR products, will help us navigate licensing and production of exosome non-invasive oncology assay."

Mr. Zdechlik, an in-vitro diagnostic industry veteran, has been with Roche Diagnostics for over 22 years, including 15 years in the clinical molecular diagnostics field. He served as a founding commercial team member of Roche Diagnostic's U.S. clinical molecular diagnostics group and has held executive level positions including sales management, corporate development and strategic marketing. His responsibilities included leading the effort to seek new technologies, evaluating new business opportunities for the U.S. diagnostic business, developing strategic investment and action plans to achieve U.S. market leadership for key Roche business platforms, directing efforts to ensure that clinical endpoints, clinical trial design, publication strategy, market development strategy, key opinion leader development and health economic strategy for high value technologies were aligned with the market needs to achieve peak product sales faster.

"This is one of the more exciting technologies I have seen in molecular diagnostics," said Zdechlik. "Exosome's technology has the potential to enable a series of companion and tumor profiling diagnostics which deliver valuable information for clinicians to precisely monitor cancer status and manage available therapies."

About Exosome Diagnostics

Exosome Diagnostics is a developer of proprietary molecular diagnostic tests with applications in oncology and metabolic disease. The company's core technology is based on the discovery that circulating nanovesicles called exosomes contain unique genetic markers that can be reliably harvested from blood and urine and used diagnostically. For more information, visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exosome Diagnostics Announces Additions to Management Team
2. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
3. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
4. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
5. Strategic Diagnostics Updates Roth Conference Presentation Time
6. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
7. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
8. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
9. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
10. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
11. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Houston Methodist Willowbrook Hospital has signed ... to serve as their official health care provider. ... will provide sponsorship support, athletic training services, and ... volunteers, athletes and families. "We are ... and to bring Houston Methodist quality services and ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... FRANCISCO , June 22, 2016  Amgen (NASDAQ: ... sponsorship of the QB3@953 life sciences incubator ... human health. The shared laboratory space at QB3@953 was ... overcome a key obstacle for many early stage organizations ... part of the sponsorship, Amgen launched two "Amgen Golden ...
Breaking Biology Technology:
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):